Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Cash & Equivalents (2016 - 2025)

Perspective Therapeutics' Cash & Equivalents history spans 16 years, with the latest figure at $174.1 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 34.99% year-over-year to $174.1 million; the TTM value through Sep 2025 reached $174.1 million, down 34.99%, while the annual FY2024 figure was $61.6 million, 566.59% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $174.1 million at Perspective Therapeutics, down from $191.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $267.8 million in Q3 2024 and bottomed at $9.2 million in Q4 2023.
  • The 5-year median for Cash & Equivalents is $61.6 million (2024), against an average of $94.7 million.
  • The largest annual shift saw Cash & Equivalents skyrocketed 3079.9% in 2021 before it plummeted 69.22% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $60.4 million in 2021, then crashed by 65.22% to $21.0 million in 2022, then crashed by 55.99% to $9.2 million in 2023, then skyrocketed by 566.59% to $61.6 million in 2024, then soared by 182.72% to $174.1 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Cash & Equivalents are $174.1 million (Q3 2025), $191.6 million (Q2 2025), and $211.7 million (Q1 2025).